DEINOVE- Second convening to a Combined General Meeting on May 30, 2022
May 19 2022 - 11:45AM
GlobeNewswire Inc.
DEINOVE- Second convening to a Combined General Meeting on May 30,
2022
DEINOVE- Second convening to a Combined
General Meeting on May 30, 2022
DEINOVE (Euronext Growth Paris: ALDEI), a French
biotech company, pioneer in the exploration and exploitation of
bacterial biodiversity to address the urgent, global challenge of
antibiotic resistance, informs its shareholders that the combined
Annual General Meeting (AGM) held on May 18, 2022 was unable to
deliberate as the required quorum was not reached, and that a new
combined AGM will be held on May 30, 2022 at 3 pm CEST, in the
premises of Fieldfisher, 48 rue Cambon, 75001 Paris, to deliberate
on the same agenda.
The shareholders taking part in the vote at
DEINOVE's Combined Annual General Meeting held yesterday owned
collectively 1,946,309 shares with voting rights out of a total of
33,308,806 shares with voting rights, or 5.84%. Consequently, in
the absence of the required quorum the General Meeting could not
validly deliberate on the ordinary and extraordinary resolutions
set out in the meeting notice published in the French official
legal bulletin Bulletin des Annonces Légales Obligatoires (BALO) no
44, dated April 13, 2022.
The shareholders are therefore invited to a
second Combined General Meeting to be held on Monday, May 30, 2022
at 3 pm CEST in the premises of Fieldfisher, 48 rue Cambon,
75001 Paris, to deliberate on the same agenda. A second convening
notice will be published on May 20, 2022 in the BALO and in a legal
newspaper.
All the documents regarding this AGM will be
available on the Company’s website as from May 20, 2022:
https://www.deinove.com/en/investor-room/documentation-center/general-shareholders-meeting-preparatory-documents
As a precaution, DEINOVE’s shareholders are
encouraged to anticipate their votes and to favor the use of postal
votes or proxy votes to take part in the AGM.
The shareholders’ vote for the first AGM remains
valid and counted for the second AGM.
The shareholders are strongly encouraged to vote
in advance via email.
Forms for postal vote or proxy
vote:
- Available on request to the Company
(assemblee-generale@deinove.com)
- Downloadable on the Company’s website:
https://www.deinove.com/en/investor-room/documentation-center/general-shareholders-meeting-preparatory-documents
Deadline for considering voting
forms:Friday, May 27, 2022 at 00:00 AM CEST.
Sending methods:
- By post: DEINOVE – A l’attention de
Monsieur Mario ALCARAZ, 1682, rue de la Valsière - CAP SIGMA, ZAC
EUROMEDECINE II - 34790 Grabels
- By email:
assemblee-generale@deinove.com
Supporting documents:
- Registered shareholders: none
- Bearer shareholders: certificate of
account registration delivered by their account-holding
institution.
Our investor relations team is available for any
additional question: assemblee-generale@deinove.com
ABOUT DEINOVE
DEINOVE is a French biotechnology company
pioneering the exploration of a new domain of life, unexplored at
99.9%: the “microbial dark matter”. By revealing the metabolic
potential of rare bacteria or still classified as uncultivable, it
tackles a global health and economic challenge: antimicrobial
resistance.The new therapies discovered and developed by DEINOVE
target superbugs (microbes that have become resistant to one or
more antimicrobials) that cause life-threatening infections which
are now spreading at high speed.This breakthrough approach gave
rise to one of the world’s first specialized microbiotechnology
platforms and a unique collection of nearly 10,000 rare strains and
thousands of bacterial extracts. Today, DEINOVE is conducting
several development programs, of which its first antibiotic
candidate is currently evaluated in a Phase II clinical trial in
severe Clostridioides difficile infections, one of the world’s
first emergencies. Located at the heart of the Euromedecine park in
Montpellier, DEINOVE has been listed on EURONEXT GROWTH® (ALDEI -
code ISIN FR0010879056) since 2010. The Company has around 50
employees and relies on a network of world-class academic,
technological, industrial and institutional partners.
CONTACTS
InvestorsMario AlcarazChief Financial and Administrative Officer+33
(0)4 48 19 01 00ir@deinove.comMediaATCG Partners – Marie PUVIEUX+33
(0)9 81 87 46 72 / +33 (0)6 10 54 36
72communication@deinove.com |
|
Deinove (EU:ALDEI)
Historical Stock Chart
From Mar 2023 to Apr 2023
Deinove (EU:ALDEI)
Historical Stock Chart
From Apr 2022 to Apr 2023